Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
tinengotinib (TT-00420)
i
Other names:
TT-00420, TT 00420, TT00420
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(16)
News
Trials
Company:
TransThera Biosci
Drug class:
Multi-tyrosine kinase inhibitor
Related drugs:
‹
sorafenib (180)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
sorafenib (180)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
›
Associations
(16)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Cholangiocarcinoma
No biomarker
Cholangiocarcinoma
TT-00420
Sensitive: B - Late Trials
TT-00420
Sensitive
:
B
TT-00420
Sensitive: B - Late Trials
TT-00420
Sensitive
:
B
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
TT-00420
Sensitive
:
C2
TT-00420
Sensitive: C2 – Inclusion Criteria
TT-00420
Sensitive
:
C2
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
TT-00420
Sensitive
:
C2
TT-00420
Sensitive: C2 – Inclusion Criteria
TT-00420
Sensitive
:
C2
FGFR2 mutation
Solid Tumor
FGFR2 mutation
Solid Tumor
TT-00420
Sensitive: C2 – Inclusion Criteria
TT-00420
Sensitive
:
C2
TT-00420
Sensitive: C2 – Inclusion Criteria
TT-00420
Sensitive
:
C2
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
FGFR2 E565A
Cholangiocarcinoma
FGFR2 E565A
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
FGFR2 E565G
Cholangiocarcinoma
FGFR2 E565G
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
FGFR2 E565K
Cholangiocarcinoma
FGFR2 E565K
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
FGFR2 V564F
Cholangiocarcinoma
FGFR2 V564F
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
FGFR2 V564I
Cholangiocarcinoma
FGFR2 V564I
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
FGFR2 N549K
Cholangiocarcinoma
FGFR2 N549K
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
FGFR2 V564L
Cholangiocarcinoma
FGFR2 V564L
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
FGFR2 N549D
Cholangiocarcinoma
FGFR2 N549D
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
FGFR2 N549T
Cholangiocarcinoma
FGFR2 N549T
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
FGFR2 N549H
Cholangiocarcinoma
FGFR2 N549H
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
TT-00420
Sensitive: C3 – Early Trials
TT-00420
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login